In the following video, Motley Fool health-care analyst David Williamson takes a look at EliLilly's strong 3.6% dividend yield. David tells us that while 3.6% is a slightly higher yield than some of Eli's American peers, there may be several potential looming threats to the company's dividend. David highlights those threats for investors and tells us how concerned we should be.
Is Eli Lilly a buy or sell?
With two of its top three drugs poised to lose patent protection this year, is Eli Lilly a dividend stock headed nowhere fast? In a new premium report, The Motley Fool's senior pharmaceuticals analyst breaks down all of Lilly's moving parts, including an in-depth analysis of the company's must-know opportunities and reasons to buy and sell today. To find out more, click here to claim your copy today.
The article Eli Lilly: Strong Sustainable Dividend? originally appeared on Fool.com.
David Williamson and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.